Overview


According to FutureWise analysis, the market for Adult Vaccines is estimated to be US$ 17.92 billion in 2023 and is expected to reach US$ 31.54 billion by 2031 at a CAGR of 7.32% over the forecast period of 2023-2031.

The vaccine is a biological preparation designed to provide active acquired immunity to a specific infection or malignant disease. They work by introducing a weakened, inactivated, or partial form of the disease-causing agent (such as a virus or bacteria) into the body. This exposure triggers the immune response, producing antibodies and memory cells that can be recognized and fight off the actual pathogens if the person is exposed to them in the future. Vaccines are known to be the best public health intervention, aiding in preventing and controlling numerous infectious diseases, some of which were the deadliest and most widespread. 

Vaccines can be prophylactic, used to prevent the effect of future infection by any pathogens, or therapeutic, which fights a disease that has already occurred, such as cancer. Some vaccines work in complete prevention through full sterilizing immunity. The administration of vaccines is called vaccination. Significant achievements in eradicating smallpox and restriction of diseases, such as tetanus, polio, and measles worldwide, are possible through vaccines. COVID-19 is a recent example of how effective the vaccines are and how the vaccination drive has played a substantial role in fighting the battle.

FutureWise Market Research has published a report that provides an insightful analysis of Adult Vaccine Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Adult Vaccine Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • AstraZeneca
  • Bharat Biotech
  • Dynavax Technologies Corporation
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck and Co
  • Novartis
  • Pfizer
  • Sanofi Pasteur
  • Serum Institute of India

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Adult vaccine market:

  • Merck announced the launch of VAXEKIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Haemophilus b Conjugate and Hepatitis B Vaccine, Inactivated Poliovirus) in US, developed in partnership with Sanofi Pasteur, In June 2021

The adult vaccine market has been growing in recent years, and after the COVID-19 pandemic, the surge of this market has increased in every manner. With the growing aging population, there is an increase in the prevalence of chronic disease and weakened immune systems in older adults that can be taken care of by administering vaccines that can protect these vulnerable populations from severe infections and complications is a driving factor for the market growth. Increased awareness and education initiatives retaken by private and public organizations bolstered market growth. Funds raised by the government for R&D and clinical drug trials are creating new opportunities for the upcoming development of this market. Vaccination recommendations by national and international organizations such as WHO and NHM are updating vaccination recommendations for adults, which has increased vaccination adoption levels and fueled the market revenue growth.

However, the vaccine market is growing; several factors can act as restraints to the market growth. Limited awareness and education among the general public and some healthcare providers; also, some adults are unaware of the specific vaccines essential at certain periods. Some people have skepticism regarding the vaccine, which leads to vaccine hesitancy and can significantly hamper the market growth as they are more concerned about the side effects of vaccine ingredients or distrust the healthcare system. The cost of the vaccines and accessibility can be a significant barrier for some adults, especially with low-income populations, which again restrain the market growth.

By Type

  • Preventive Vaccine
  • Therapeutic Vaccine

By Disease

  • Measles
  • Mumps
  • Varicella
  • DPT
  • Hepatitis
  • Influenza
  • Typhoid
  • Meningococcal
  • Pneumococcal
  • Zoster Shingles
  • Rubella

By Technology

  • Non-Live Attenuated Vaccines
  • Inactivated Viral/Bacterial Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America accounts for the largest market share due to the development of new vaccines such as human papillomavirus and rotavirus vaccines, the growing patient population, the rising healthcare industry, stable healthcare infrastructure, and expansion of healthcare expenditure. In addition, funds raised by the government for research and development for the advancement in vaccines interventions and more studies about the vaccines for effective results are growing the market in this region.


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the of Adult Vaccine Market By Type, By Technology, By Diseases, and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections, which are represented in the format of data sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors, which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Adult Vaccines Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Adult Vaccines Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Adult Vaccines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Adult Vaccines Market, By Disease Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Measles
        2. Mumps
        3. Varicella
        4. DPT
        5. Hepatitis
        6. Influenza
        7. Typhoid
        8. Meningococcal
        9. Pneumococcal
        10. Zoster Shingles
        11. Rubella

  • 8.   Adult Vaccines Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Preventive Vaccine
        2. Therapeutic Vaccine

  • 9.   Adult Vaccines Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Non-Live Attenuated Vaccines
        2. Inactivated Viral/Bacterial Vaccines
        3. Toxoid Vaccines
        4. Recombinant Vaccines
        5. Conjugate Vaccines

  • 10.   North America Adult Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Adult Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Adult Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Adult Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Adult Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AstraZeneca
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bharat Biotech
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Dynavax Technologies Corporation
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. GlaxoSmithKline
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Johnson & Johnson
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merck & Co
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Novartis
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Pfizer
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sanofi Pasteur
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Serum Institute of India
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients